This modification resulted in a poorer overall 8-year disease-free survival (89.2% ± 1.3% vs. 92.3% ± 1.2%) and overall survival (96.1% ± 0.8% and 98.0% ± 0.6%) except for the patients with ETV6-RUNX1-positive ALL or ages of 1 to 6 years who fared equally well in both treatment arms. The gene discussed is RUNX1; the disease is acute lymphoblastic leukemia.